HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17

HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on CytomX Therapeutics (NASDAQ: CTMX) and increased the price target from $10 to $17.